Trial Profile
A Phase II Study of Ibrutinib Plus Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients With Newly Diagnosed MCL
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Feb 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 11 Jan 2022 Planned End Date changed from 31 Jul 2021 to 31 Jul 2024.
- 11 Jan 2022 Planned primary completion date changed from 31 Jul 2021 to 31 Jul 2024.
- 19 Nov 2021 Results (n=50) of the previously untreated mantle cell lymphoma patients cohort were published in the Journal of Clinical Oncology.